Top

Clinical Reviews in Allergy & Immunology

Published in:

29-09-2021 | Systemic Lupus Erythematosus

Antimitochondrial Antibodies: from Bench to Bedside

Authors: Francesca Colapietro, Ana Lleo, Elena Generali

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2022

Abstract

Anti-mitochondrial antibodies (AMA) are directed against the E2 subunits of the 2-oxo acid dehydrogenase complexes (PDC-E2) and are the typical biomarkers of primary biliary cholangitis (PBC), being present in 90–95% of patients, with increasing sensitivity at increasing titers. Albeit being highly specific for PBC diagnosis, AMA can be detected in less than 1% of healthy subjects, and thus the management subjects with no sign or symptom of liver disease is still a challenge and data concerning clinical risk of developing PBC in this subgroup of patients are controversial. Moreover, AMA can also be detected in patients affected by overlap syndrome, as well as hepatic diseases (i.e., NASH and viral hepatitis), while the association with autoimmune diseases, in particular Sjögren’s syndrome, systemic sclerosis, and systemic lupus erythematosus, is well established. Furthermore, new associations are being identified with inflammatory myositis and heart disease. AMA are directed towards the pyruvate dehydrogenase multi enzyme complex (PDC-E2) subunit, which represents an epithelial specific autoantigen for PBC. This review focuses on the main characteristics of AMA, their association with autoimmune diseases and liver diseases.

Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al (2003) Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus. N Engl J Med 349(16):1526–33CrossRef

Gulamhusein AF, Hirschfield GM (2018) Pathophysiology of primary biliary cholangitis. Best Pract Res Clin Gastroenterol 34–35:17–25CrossRef

Bogdanos D-P, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y et al (2004) Disease-specific cross-reactivity between mimicking peptides of heat shock protein of mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun 22(4):353–62CrossRef

Chantran Y, Ballot É, Johanet C (2013) Autoantibodies in primary biliary cirrhosis: Antimitochondrial autoantibodies. Clin Res Hepatol Gastroenterol 37(4):431–3CrossRef

Calise SJ, Zheng B, Hasegawa T, Satoh M, Isailovic N, Ceribelli A et al (2018) Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies. Clin Chem Lab Med 56(10):1789–98CrossRef

Patel D, Egner W, Gleeson D, Wild G, Ward A (2002) Detection of serum M2 anti-mitochondrial antibodies by enzyme-linked immunosorbent assay is potentially less specific than by immunofluorescence. Ann Clin Biochem 39(3):304–7CrossRef

Dähnrich C, Pares A, Caballeria L, Rosemann A, Schlumberger W, Probst C et al (2009) New ELISA for Detecting Primary Biliary Cirrhosis-Specific Antimitochondrial Antibodies. Clin Chem 55(5):978–85CrossRef

Poyatos E, Morandeira F, Climent J, Mas V, Castellote J, Bas J (2021) Detection of anti-mitochondrial 2-oxoacid dehydrogenase complex subunit’s antibodies for the diagnosis of primary biliary cholangitis. Clinical Immunol 108749

Berg PA, Klein R (1992) Antimitochondrial Antibodies in Primary Biliary Cirrhosis and Other Disorders: Definition and Clinical Relevance. Dig Dis 10(2):85–101CrossRef

10.

Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB (2008) Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis 12(2):261–276CrossRef

11.

Klein R, Berg PA (1988) Characterization of a new mitochondrial antigen-antibody system (M9/anti-M9) in patients with anti-M2 positive and anti-M2 negative primary biliary cirrhosis. Clin Exp Immunol 74(1):68–74

12.

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DEJ, Lindor K et al (2015) Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis.’ J Hepatol 63(5):1285–1287CrossRef

13.

Lleo A, Colapietro F (2018) Changes in the epidemiology of primary biliary cholangitis. Clin Liver Dis 22(3):429–441CrossRef

14.

Selmi C, Bowlus CL, Gershwin ME, Coppel RL (2011) Primary biliary cirrhosis. The Lancet 377(9777):1600–1609CrossRef

15.

Kaplan MM, Gershwin ME (2005) Primary biliary cirrhosis. N Engl J Med 353(12):1261–1273CrossRef

16.

Lleo A, Wang GQ, Gershwin ME, Hirschfield GM (2020) Primary biliary cholangitis. The Lancet 396(10266):1915–1926CrossRef

17.

Hirschfield GM, Beuers U, Corpechot C, Invernizzi P, Jones D, Marzioni M et al (2017) EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67(1):145–172CrossRef

18.

Neuberger J, Thomson R (1999) PBC and AMA? What is the connection? Hepatology 29(1):271–276CrossRef

19.

Selmi C, Generali E, Gershwin ME (2018) Rheumatic manifestations in autoimmune liver disease. Rheumatic Dis Clin North Am 44(1):65–87CrossRef

20.

Selmi C, Gershwin ME (2017) Chronic autoimmune epithelitis in Sjögren’s syndrome and primary biliary cholangitis: a comprehensive review. Rheumatol Ther 4(2):263–279CrossRef

21.

Chen RCY, Naiyanetr P, Shu SA, Wang J, Yang GX, Kenny TP et al (2013) Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology 57(4):1498–1508CrossRef

22.

Lleo A, Maroni L, Glaser S, Alpini G, Marzioni M (2014) Role of cholangiocytes in primary biliary cirrhosis. Semin Liver Dis 34(3):273–284CrossRef

23.

Lleo A, Leung PSC, Hirschfield GM, Gershwin EM (2020) The pathogenesis of primary biliary cholangitis: a comprehensive review. Semin Liver Dis 40(01):034–048CrossRef

24.

Shuai Z, Wang J, Badamagunta M, Choi J, Yang G, Zhang W et al (2017) The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology 65(5):1670–1682CrossRef

25.

Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF (1996) Natural history of early primary biliary cirrhosis. The Lancet 348(9039):1399–1402CrossRef

26.

Zandanell S, Strasser M, Feldman A, Tevini J, Strebinger G, Niederseer D et al (2020) Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody-positive subjects over six years of follow-up. J Intern Med 287(4):395–404CrossRef

27.

Dahlqvist G, Gaouar F, Carrat F, Meurisse S, Chazouillères O, Poupon R et al (2017) Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology 65(1):152–163CrossRef

28.

Baldo DC, Dellavance A, Ferraz MLG, Andrade LEC (2019) Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. Autoimmun Highlights 10(1):10CrossRef

29.

Ceribelli A, Isailovic N, De Santis M, Generali E, Satoh M, Selmi C (2018) Detection of anti-mitochondrial antibodies by immunoprecipitation in patients with systemic sclerosis. J Immunol Methods 452:1–5CrossRef

30.

Yamagiwa S (2014) Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance. WJG 20(10):2606CrossRef

31.

Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R (2002) Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterology 97(4):999–1002CrossRef

32.

Tang L, Zhong R, He X, Wang W, Liu J, Zhu Y et al (2017) Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis: IgG-AMA and UDCA treatment. J Gastroenterol Hepatol 32(3):659–666CrossRef

33.

Zandanell S, Strasser M, Feldman A, Strebinger G, Aigner G, Niederseer D et al (2021) Similar clinical outcome of AMA immunoblot-M2-negative compared to immunoblot-positive subjects over six years of follow-up. Postgrad Med 133(3):291–298CrossRef

34.

Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi P et al (2019) Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival. Gastroenterology 156(1):96-107.e1CrossRef

35.

Selmi C, Zuin M, Bowlus CL, Gershwin ME (2008) Anti-mitochondrial antibody–negative primary biliary cirrhosis. Clin Liver Dis 12(1):173–185CrossRef

36.

Bizzaro N, Covini G, Rosina F, Muratori P, Tonutti E, Villalta D et al (2012) Overcoming a “probable” diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. Clinic Rev Allerg Immunol 42(3):288–297CrossRef

37.

Ozaslan E, Efe C, Ozaslan NG (2016) The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Clin Res Hepatol Gastroenterol 40(5):553–561CrossRef

38.

de Liso F, Matinato C, Ronchi M, Maiavacca R (2017) The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative PBC patients: A review of literature. Clin Chem Lab Med (CCLM) 56(1):25–31CrossRef

39.

Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A et al (1997) Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 25(5):1090–1095CrossRef

40.

Juliusson G, Imam M, Björnsson ES, Talwalkar JA, Lindor KD (2016) Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol 51(6):745–752CrossRef

41.

Granito A, Yang WH, Muratori L, Lim MJ, Nakajima A, Ferri S et al (2010) PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol 105(1):125–131CrossRef

42.

Czaja AJ, Carpenter HA (2017) Autoimmune hepatitis overlap syndromes and liver pathology. Gastroenterol Clin North Am 46(2):345–364CrossRef

43.

Czaja A (2001) Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 34(4):659–665CrossRef

44.

Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37(5):1202–1219CrossRef

45.

Adams LA, Lindor KD, Angulo P (2004) The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 99(7):1316–1320CrossRef

46.

Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S (2004) Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol 38(9):801–804CrossRef

47.

Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone AM et al (2003) Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 48(11):2173–2181CrossRef

48.

Vuppalanchi R, Gould RJ, Wilson LA, Unalp-Arida A, Cummings OW, Chalasani N et al (2012) Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 6(1):379–385CrossRef

49.

Ravi S, Shoreibah M, Raff E, Bloomer J, Kakati D, Rasheed K et al (2015) Autoimmune markers do not impact clinical presentation or natural history of steatohepatitis-related liver disease. Dig Dis Sci 60(12):3788–3793CrossRef

50.

Weber S, Benesic A, Buchholtz ML, Rotter I, Gerbes AL (2021) Antimitochondrial rather than antinuclear antibodies correlate with severe drug-induced liver injury. Dig Dis 39(3):275–282CrossRef

51.

Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M et al (1995) High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 21(3):613–619

52.

Luo JC, Hwang SJ, Li CP, Lu RH, Chan CY, Wu JC et al (1998) Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: negative role of serum viral titre and genotype. J Gastroenterol Hepatol 13(5):475–479CrossRef

53.

Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R et al (1997) Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 26(3):561–566CrossRef

54.

Chen CH, Lee CM, Chen CH, Hu TH, Wang JH, Hung CH et al (2010) Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C. Chang Gung Med J 33(3):258–265

55.

Generali E, De Santis M, Isailovic N, Palermo B, Guidelli GM, Ceribelli A et al (2021) Rheumatoid factor and anti-citrullinated peptide antibodies in the general population: hepatitis B and C virus association and 15-year-risk of rheumatoid arthritis. Clin Exp Rheumatol 39(1):38–43CrossRef

56.

Gilman AJ, Le AK, Zhao C, Hoang J, Yasukawa LA, Weber SC et al (2018) Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations. BMJ Open Gastroenterol 5(1):e000203

57.

Floreani A, Franceschet I, Cazzagon N, Spinazzè A, Buja A, Furlan P et al (2015) Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol 48(2–3):192–197CrossRef

58.

Floreani A, Mangini C, Reig A, Franceschet I, Cazzagon N, Perini L et al (2017) Thyroid dysfunction in primary biliary cholangitis: A comparative study at two European centers. Am J Gastroenterol 112(1):114–119CrossRef

59.

Efe C, Torgutalp M, Henriksson I, Alalkim F, Lytvyak E, Trivedi H et al (2021) Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence and significance for clinical presentation and disease outcome. J Gastroenterol Hepatol 36(4):936–942CrossRef

60.

Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P et al (2009) Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 36(10):2250–2256CrossRef

61.

Rigamonti C (2006) Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 55(3):388–394CrossRef

62.

Liberal R, Grant CR, Sakkas L, Bizzaro N, Bogdanos DP (2013) Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol 37(6):572–585CrossRef

63.

Norman GL, Bialek A, Encabo S, Butkiewicz B, Wiechowska-Kozlowska A, Brzosko M et al (2009) Is prevalence of PBC underestimated in patients with systemic sclerosis? Dig Liver Dis 41(10):762–764CrossRef

64.

Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685–1699CrossRef

65.

Cavazzana I, Ceribelli A, Taraborelli M, Fredi M, Norman G, Tincani A et al (2011) Primary biliary cirrhosis-related autoantibodies in a large cohort of Italian patients with systemic sclerosis. J Rheumatol 38(10):2180–2185CrossRef

66.

Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W (2016) The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis 75(1):136–141CrossRef

67.

Menon M, Blair PA, Isenberg DA, Mauri C (2016) A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity 44(3):683–697CrossRef

68.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725CrossRef

69.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277CrossRef

70.

Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686CrossRef

71.

Li CH, Xu PS, Wang CY, Zou GL (2006) Increased serum aminotransferases associated with anti-mitochondrial antibodies in systemic lupus erythematosus patients with autoimmune liver disease. Clin Chim Acta 365(1–2):135–142CrossRef

72.

Garcia D, Erkan D (2018) Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 378(21):2010–2021CrossRef

73.

Selmi C, De Santis M, Battezzati PM, Generali E, Lari SA, Ceribelli A et al (2020) Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population. Int J Cardiol 300:209–213CrossRef

74.

Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S et al (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2(8361):1211–1214CrossRef

75.

Becker YL, Julien AS, Godbout A, Boilard É, Fortin PR (2020) Pilot study of anti-mitochondrial antibodies in antiphospholipid syndrome. Lupus 29(12):1623–1629CrossRef

76.

Ahmad A, Heijke R, Eriksson P, Wirestam L, Kechagias S, Dahle C et al (2021) Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes. Clin Exp Immunol 203(1):22–31CrossRef

77.

Becker Y, Loignon RC, Julien AS, Marcoux G, Allaeys I, Lévesque T et al (2019) Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. Sci Rep 9(1):4530CrossRef

78.

Lai JH, Hung LF, Huang CY, Wu DW, Wu CH, Ho LJ (2021) Mitochondrial protein CMPK2 regulates IFN alpha-enhanced foam cell formation, potentially contributing to premature atherosclerosis in SLE. Arthritis Res Ther 23(1):120CrossRef

79.

Vivino FB (2017) Sjogren’s syndrome: clinical aspects. Clin Immunol 182:48–54CrossRef

80.

Theander E, Jacobsson LTH (2008) Relationship of Sjögren’s syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am 34(4):935–47, viii–ix

81.

Generali E, Costanzo A, Mainetti C, Selmi C (2017) Cutaneous and mucosal manifestations of Sjögren’s syndrome. Clin Rev Allergy Immunol 53(3):357–370CrossRef

82.

Yao Y, Ma JF, Chang C, Xu T, Gao CY, Gershwin ME et al (2021) Immunobiology of T cells in Sjögren’s syndrome. Clin Rev Allergy Immunol 60(1):111–131CrossRef

83.

Shen L, Suresh L (2017) Autoantibodies, detection methods and panels for diagnosis of Sjögren’s syndrome. Clin Immunol 182:24–29CrossRef

84.

Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM et al (2017) 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76(1):9–16CrossRef

85.

Chen CT, Tseng YC, Yang CW, Lin HH, Chen PJ, Huang TY et al (2016) Increased risks of spontaneous bacterial peritonitis and interstitial lung disease in primary biliary cirrhosis patients with concomitant Sjögren syndrome. Medicine 95(2):e2537

86.

Ni P, Men R, Shen M, Wang T, Huang C, Fan X et al (2019) Concomitant Sjögren’s syndrome was not associated with a poorer response or outcomes in ursodeoxycholic acid-treated patients with primary biliary cholangitis. Can J Gastroenterol Hepatol 2019:7396870CrossRef

87.

Marasini B (2001) Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 60(11):1046–1049CrossRef

88.

Caramella C, Avouac J, Sogni P, Puéchal X, Kahan A, Allanore Y (2007) Association between rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 74(3):279–281CrossRef

89.

Sorensen HT, Thulstrup AM, Blomqvist P, Nørgaard B, Fonager K, Ekbom A (1999) Risk of primary biliary liver cirrhosis in patients with coeliac disease: Danish and Swedish cohort data. Gut 44(5):736–738CrossRef

90.

Kingham JG, Parker DR (1998) The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 42(1):120–122CrossRef

91.

Habior A, Lewartowska A, Orłowska J, Zych W, Sankowska M, Bauer A et al (2003) Association of coeliac disease with primary biliary cirrhosis in Poland. Eur J Gastroenterol Hepatol 15(2):159–164CrossRef

92.

Bardella MT, Quatrini M, Zuin M, Podda M, Cesarini L, Velio P et al (1997) Screening patients with celiac disease for primary biliary cirrhosis and vice versa. Am J Gastroenterol 92(9):1524–1526

93.

Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL (2017) A comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52(1):1–19CrossRef

94.

Ceribelli A, Isailovic N, De Santis M, Generali E, Fredi M, Cavazzana I et al (2017) Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol 36(2):469–475CrossRef

95.

Minamiyama S, Ueda S, Nakashima R, Yamakado H, Sakato Y, Yamashita H et al (2020) Thigh muscle MRI findings in myopathy associated with anti-mitochondrial antibody. Muscle Nerve 61(1):81–87CrossRef

96.

Maeda MH, Tsuji S, Shimizu J (2012) Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain 135(6):1767–1777CrossRef

97.

Albayda J, Khan A, Casciola-Rosen L, Corse AM, Paik JJ, Christopher-Stine L (2018) Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement. Semin Arthritis Rheum 47(4):552–556CrossRef

98.

Kadosaka T, Tsujinaga S, Iwano H, Kamiya K, Nagai A, Mizuguchi Y et al (2020) Cardiac involvement with anti-mitochondrial antibody-positive myositis mimicking cardiac sarcoidosis. ESC Heart Failure 7(6):4315–4319CrossRef

99.

Schultheiss H, Bolte H (1985) Immunological analysis of auto-antibodies against the adenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol 17(6):603–617CrossRef

100.

Bartoli A, Gitto S, Sighinolfi P, Cursaro C, Andreone P (2021) Primary biliary cholangitis associated with SARS-CoV-2 infection. J Hepatol 74(5):1245–1246CrossRef

101.

Hatzis GS, Fragoulis GE, Karatzaferis A, Delladetsima I, Barbatis C, Moutsopoulos HM (2008) Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren’s syndrome. J Rheumatol 35(10):2012–2016

102.

Imura-Kumada S, Hasegawa M, Matsushita T, Hamaguchi Y, Encabo S, Shums Z et al (2012) High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Mod Rheumatol 22(6):892–898CrossRef

103.

Ranua J, Luoma K, Auvinen A, Haapala A-M, Mäki M, Peltola J et al (2005) Antimitochondrial antibodies in patients with epilepsy. Epilepsy Behav 7(1):95–97CrossRef

104.

Laadhar L, Zitouni M, Kallel-Sellami M, Bouguerra R, Chaabouni H, Makni S (2007) Spectrum of autoantibodies in Tunisian adult type 1 diabetes mellitus. Ann N Y Acad Sci 1107:356–362CrossRef

105.

Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, Homburger HA et al (2007) Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 46(3):785–792CrossRef

106.

Li BA, Liu J, Hou J, Tang J, Zhang J, Xu J et al (2015) Autoantibodies in Chinese patients with chronic hepatitis B: prevalence and clinical associations. World J Gastroenterol 21(1):283–291CrossRef

107.

Liu CW, Huang YC (2018) Vitiligo and autoantibodies: a systematic review and meta-analysis. J Dtsch Dermatol Ges 16(7):845–851

108.

Marconcini ML, Fayad L, Shiozawa MBC, Dantas-Correa EB, de Lucca Schiavon L, Narciso-Schiavon JL (2013) Autoantibody profile in individuals with chronic hepatitis C. Rev Soc Bras Med Trop 46(2):147–153CrossRef

109.

Mattalia A, Quaranta S, Leung PS, Bauducci M, Van de Water J, Calvo PL et al (1998) Characterization of antimitochondrial antibodies in health adults. Hepatology 27(3):656–61

110.

Pelka K, Stec-Polak M, Wojas-Pelc A, Pastuszczak M (2021) Prevalence of antimitochondrial antibodies in subacute cutaneous lupus erythematosus. Int J Dermatol 60(1):88–92CrossRef

111.

Pope JE, Thompson A (1999) Antimitochondrial antibodies and their significance in diffuse and limited scleroderma. J Clin Rheumatol 5(4):206–209CrossRef

112.

Ramos-Casals M, Pares A, Jara LJ, Solans R, Viñas O, Vázquez P et al (2005) Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. J Viral Hepat 12(6):648–654CrossRef

113.

Shibata M, Onozuka Y, Morizane T, Koizumi H, Kawaguchi N, Miyakawa H et al (2004) Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture. J Gastroenterol 39(3):255–259CrossRef

114.

Beretta-Piccoli BT, Ripellino P, Gobbi C, Cerny A, Baserga A, Di Bartolomeo C et al (2018) Autoimmune liver disease serology in acute hepatitis E virus infection. J Autoimmun 94:1–6CrossRef

115.

Turchany JM, Uibo R, Kivik T, Van de Water J, Prindiville T, Coppel RL et al (1997) A study of antimitochondrial antibodies in a random population in Estonia. Am J Gastroenterol 92(1):124–6

116.

Wielosz E, Majdan M, Koszarny A, Dryglewska M, Tabarkiewicz J (2016) Presence of organ-specific antibodies in patients with systemic sclerosis. Pol Arch Med Wewn 126(11):862–869

117.

Yokokawa T, Yoshihisa A, Misaka T, Sato T, Kaneshiro T, Oikawa M et al (2021) Anti-mitochondrial antibodies in patients with dilated cardiomyopathy. Intern Med 60(2):201–208CrossRef

118.

Zografos TA, Gatselis N, Zachou K, Liaskos C, Gabeta S, Koukoulis GK et al (2012) Primary biliary cirrhosis-specific autoantibodies in first degree relatives of Greek primary biliary cirrhosis patients. World J Gastroenterol 18(34):4721–4728CrossRef

Title: Antimitochondrial Antibodies: from Bench to Bedside
Authors: Francesca Colapietro
Ana Lleo
Elena Generali
Publication date: 29-09-2021
Publisher: Springer US
Keywords: Systemic Lupus Erythematosus
Systemic Sclerosis
Primary Biliary Cholangitis
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2022
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-021-08904-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies

Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis

An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations

Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice

Serum ANCA as Disease Biomarkers: Clinical Implications Beyond Vasculitis

Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage